Congress mandates rebate pass-through, bans PBM steering of patients to affiliated pharmacies

What it does

This bill establishes new requirements for pharmacy benefit managers (PBMs) under Medicare Part D and Medicaid, effective January 1, 2027. It requires PBMs to reimburse pharmacies based on actual drug acquisition costs plus a small markup, pass manufacturer rebates directly to patients at the point of sale, prohibit steering patients to affiliated pharmacies, and report compliance annually. Violations carry criminal penalties up to 10 years imprisonment and $1 million fines. Pharmacists and independent pharmacies benefit by receiving fairer reimbursement; patients benefit from lower out-of-pocket costs through rebate pass-through; PBMs and their affiliated pharmacies face restrictions on profit-taking and steering practices.

Why we flagged it

The bill's core mechanism is regulatory: it mandates specific reimbursement formulas, rebate pass-through, and anti-steering rules for PBMs in Medicare and Medicaid. This is not a tax measure, appropriation, or commemorative act—it is direct structural regulation of an intermediary industry.

What the text implies

• Rebate pass-through at point of sale may reduce plan sponsors' ability to negotiate volume discounts with manufacturers, potentially raising overall drug costs for plans and shifting negotiating power upstream.
• Mandatory rebate remittance to the Secretary for low-income beneficiaries creates a new federal revenue stream from PBM rebates, effectively converting private rebates into public funds.
• Steering prohibition is broadly defined to include network design, accreditation standards, and day-supply limits—provisions PBMs currently use to manage costs; enforcement may require significant CMS resources.
• Pharmacy survey reporting requirement (Section 3) expands data collection on net acquisition prices across all pharmacy types, potentially enabling future reimbursement rate-setting that disadvantages certain pharmacy formats.
• Criminal penalties (10 years, $1M) for PBM violations are unusually severe for regulatory non-compliance; enforcement discretion and prosecutorial burden are not addressed.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary patients gain lower out-of-pocket costs through mandatory rebate pass-through at point of sale, and independent pharmacies gain fair reimbursement protection. PBMs lose the ability to underpay pharmacies and capture rebates, which were previously hidden costs borne by patients and smaller pharmacies.

Who stands to gain

• independent and community pharmacies
• retail pharmacies
• Medicare Part D beneficiaries (lower copays/coinsurance)
• Medicaid beneficiaries (lower copays)

Named in the bill

Pharmacy Benefit Managers (PBMs), Medicare Part D (prescription drug plans), Medicaid, Centers for Medicare & Medicaid Services (CMS), PDP sponsors, Managed care entities, Drug manufacturers, Retail pharmacies, Mail-order pharmacies, Specialty pharmacies

Where it stands

41 cosponsors: 25 Republicans, 16 Democrats.

• Dec 11, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 11, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

9 lobbying clients named this bill on 12 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $11,412,656 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 89% of bills with at least one filing.

Jake Auchincloss, the sponsor, reported $785,750 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $6,472,656 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Bluecross Blueshield of Tennessee — $570,000 on 1 filing
• National Association of Chain Drug Stores — $290,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.